FDA approves taletrectinib for ROS1-positive non-small cell lung cancer
On June 11, 2025, the Food and Drug Administration approved taletrectinib (Ibtrozi, Nuvation Bio Inc.), a kinase inhibitor, for adults with locally advanced or metastatic ROS1-positive non-small ...
With lung cancer FDA nod, it's David versus Goliath
Jun 11, 2025 · Nuvation Bio has won FDA approval for Ibtrozi, or taletrectinib, to challenge existing meds from Pfizer, BMS and Roche in ROS1-positive lung cancer.
Ibtrozi for Non-Small-Cell Lung Cancer - WebMD
Ibtrozi is a medicine called a kinase inhibitor that is used to treat a certain type of lung cancer called non-small-cell lung cancer (NSCLC) that is caused by an abnormal ROS1 gene.
Ibtrozi: Uses, Dosage, Side Effects & Warnings - Drugs.com
Jun 12, 2025 · Ibtrozi is used to treat non-small cell lung cancer (NSCLC) in adults that has spread within the chest or to other parts of the body and is caused by an abnormal ROS1 …
Taletrectinib Approved by FDA for ROS1+ Non-Small Cell Lung Cancer
Jun 11, 2025 · The tyrosine kinase inhibitor taletrectinib has been approved for use in patients with ROS1-positive non-small cell lung cancer. The FDA has granted approval to the tyrosine …
FDA Approves Talectrectinib (Ibtrozi) for ROS1-Positive Lung Cancer
On June 11, 2025, the U.S. Food and Drug Administration (FDA) approved taletrectinib (Ibtrozi), a new targeted therapy for adults with locally advanced or metastatic ROS1-positive non-small …
U.S. Food and Drug Administration Approves Nuvation Bio’s IBTROZI …
Jun 11, 2025 · “The FDA approval of IBTROZI marks a major milestone in the evolution of targeted therapy for advanced ROS1-positive NSCLC,” said David Hung, M.D., Founder, …
FDA Approves Nuvation Bio’s IBTROZI™ for Advanced ROS1-Positive Lung Cancer
Jun 11, 2025 · “IBTROZI’s approval represents a major advance for patients with advanced ROS1-positive lung cancer, particularly those battling disease progression in the brain,” said …
FDA Approves IBTROZI for Rare Lung Cancer with 90% Response …
Jun 11, 2025 · New targeted therapy demonstrates powerful 90% response rate in ROS1+ lung cancer patients. First brain-penetrant treatment option for this rare cancer. See clinical data.
FDA Approves Taletrectinib for Advanced Non-Small Cell Lung Cancer
Jun 12, 2025 · The U.S. Food and Drug Administration approved the kinase inhibitor taletrectinib (Ibtrozi) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer.